TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The American Hospital Association, four safety-net hospitals and the Maine Hospital Association have sued to stop a Trump administration change to the 340B drug discount program scheduled for January 2027. Under the change, hospitals would pay regular prices upfront and seek rebates after dispensing drugs; the AHA estimates the system could add more than $1 billion in annual administrative costs. The administration’s defense and the lawsuit’s outcome remain pending.
The American Hospital Association (AHA), four safety-net hospitals and the Maine Hospital Association have sued the Trump administration to block a change to the federal 340B drug discount program, arguing that a rebate system set to begin in January 2027 would raise costs and add administrative work. The groups want the government to cancel the change and keep the current arrangement, under which eligible hospitals receive discounts before dispensing drugs.
Under the planned system, hospitals would first pay the regular price for medicines and then submit claims for rebates after dispensing them. The current model provides the discount upfront. The source report describes typical discounts as about 13% for generic drugs and 23% for brand-name drugs. The lawsuit seeks a return to the existing approach.
The AHA estimates the change could create more than $1 billion in annual administrative costs for hospitals. That figure is the association’s estimate, not a government finding. The Health Resources and Services Administration (HRSA), which runs the program, reported that covered entities spent $100 billion on 340B drugs in 2025, up from $81.4 billion in 2024 and $66.3 billion in 2023.
Hospitals and drugmakers disagree about the program’s effects and oversight. The Pharmaceutical Research and Manufacturers of America (PhRMA) argues that some hospitals profit from discounted medicines and that safeguards over how savings are used are inadequate. Hospital advocates counter that 340B savings help sustain services for underserved communities. Those competing claims are part of the broader dispute; they do not determine the legal question before the court.
How Rebates Could Affect Hospital Budgets
The dispute concerns when hospitals receive the discount, not just the size of the discount. Paying the full price upfront could require participating hospitals to carry higher drug expenses while waiting for rebate claims to be processed. The AHA says the system would also divert staff time and money to new administrative tasks, potentially leaving fewer resources for care.
That exposure matters especially to safety-net and rural providers, which rely on the program to support services for patients with low incomes and other community needs. The hospital groups say savings help maintain access to medicines and support behavioral health, oncology and other care. The scale of any impact will depend on how the rebate process operates, how quickly claims are paid and which entities are affected; those details are not settled in the material provided.
340B drug discount program management software
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
A Repeated Fight Over 340B Rules
The 340B program gives eligible providers access to medicines at reduced prices. It has been a longstanding point of conflict between participating hospitals and pharmaceutical companies, with disagreements over program growth, oversight and how hospitals use savings. HRSA’s reported increase in 340B drug spending has added to the debate, but the spending totals alone do not establish whether the program is being misused.
The current lawsuit is not the first challenge to a rebate-based model. The report says the Trump administration announced a similar effort last year, but courts blocked it. Maureen Testoni, president and CEO of 340B Health, a group representing more than 1,600 program participants, called the current plan a repeat of that earlier approach. The legal challenge now puts the proposed 2027 change before a federal judge again.
“The proposed shift from upfront 340B discounts to a rebate-based system would place significant financial pressure and administrative burdens on hospitals and clinics that rely on 340B savings to support essential patient care services.”
— Guy Hudson, president and CEO of Northern Light Health
Court Ruling and Rebate Details Pending
The lawsuit’s outcome is unknown, as is whether the judge will require oral arguments. The report says the case briefing is due to conclude in mid-November 2026, with a decision expected before the planned January 1 start. The supplied material does not include a ruling or a response from the administration to this lawsuit.
It is also not clear from the report how the rebate system would handle claim processing times, disputes or delayed payments in practice. The AHA’s estimate of more than $1 billion in annual administrative costs is an advocacy group’s projection; the material does not provide an independent assessment of that estimate. PhRMA’s allegations about hospital profits and spending are likewise claims made by the trade group.
Briefing Ends Before January Start
The parties are expected to finish briefing the case in mid-November. The judge will then decide whether to hold oral arguments, and a decision is expected before the rebate plan is due to take effect on January 1, 2027. A ruling could determine whether the planned shift proceeds on schedule, is blocked, or faces another legal outcome; the available report does not say what remedy the court is likely to choose.
Until the court acts or the administration changes course, hospitals and patients have no confirmed outcome. The central near-term question is whether the existing upfront discount arrangement remains in place after the scheduled start date.
Key Questions
What change to the 340B program are hospitals challenging?
The planned system would require hospitals to pay regular prices upfront for covered drugs and seek rebates after dispensing them, instead of receiving discounts at purchase.
Who filed the lawsuit?
The plaintiffs named in the report are the American Hospital Association, four safety-net hospitals and the Maine Hospital Association.
When is the rebate system scheduled to begin?
The change is scheduled to take effect on January 1, 2027. The report says the judge is expected to issue a decision before that date.
How much could the change cost hospitals?
The AHA estimates the new system could add more than $1 billion in annual administrative costs. That is the association’s estimate, and the supplied report does not provide an independent cost assessment.
What do drugmakers say about the 340B program?
PhRMA argues that some hospitals benefit financially from discounted medicines and that oversight of how savings are used is inadequate. Hospitals dispute that framing and say the savings support care and services for their communities.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
